# Strategic Partners Report: Dermatology Chains, Cancer Centers & Device Companies
**Generated:** February 11, 2026

---

## Executive Summary
Strategic partnerships can provide distribution, validation, and funding. Key targets: PE-backed dermatology chains (consolidating rapidly), NCI-designated cancer centers, and medical device companies.

---

## DERMATOLOGY CHAINS (HOT MARKET)

### Market Overview
- **10-15% of private dermatology practices** now PE-backed (2023 data)
- Consolidation accelerating — "consolidation of consolidators" phase
- Looking for technology differentiation
- **HelioFlux opportunity:** Device that improves diagnostic efficiency

### Top Targets

**1. Forefront Dermatology** ⭐ TOP PRIORITY
- **Status:** Largest dermatology group in US
- **Size:** 200+ clinics across 22 states
- **Owner:** Partners Group (acquired 2022)
- **EBITDA:** $90M+ (2021)
- **Why target:** Scale + resources + need for differentiation

**2. Schweiger Dermatology Group**
- **Size:** Major presence in NY/NJ/PA/CT
- **Funding:** $100M from LNK Partners (2022)
- **Focus:** Growth through acquisition
- **Why target:** Growing, well-funded, regional leader

**3. U.S. Dermatology Partners**
- **Owner:** Private equity backed
- **Size:** Multi-state presence
- **Why target:** Scale, standardized protocols

**4. QualDerm Partners**
- **Recent:** Rebranded to "A Skin & Aesthetics Wellness Family"
- **Focus:** Expanding into cosmetics/aesthetics
- **Why target:** Innovation-focused positioning

### Pitch Angle for Dermatology Chains
- "Improve skin cancer detection in primary care hand-offs"
- "Non-invasive triage reduces unnecessary biopsies"
- "Patient satisfaction through painless screening"
- "Differentiation from competitors"

---

## CANCER CENTERS

### NCI-Designated Comprehensive Cancer Centers
Best for clinical validation partnerships:

**1. MD Anderson Cancer Center (Houston)**
- World's largest cancer center
- Strong research programs
- Good for clinical trials

**2. Memorial Sloan Kettering (NYC)**
- Leading research institution
- Media/PR relationships
- Strong diagnostics focus

**3. Mayo Clinic Cancer Center**
- Multi-site (Rochester, Phoenix, Jacksonville)
- NOTE: Partnered with DermaSensor for their study
- Could be competitive or collaborative

**4. Moffitt Cancer Center (Tampa)**
- Hosts "Business of Biotech" conference
- Connects researchers with investors
- **Action:** Look at Moffitt partnership opportunities

**5. City of Hope (LA area)**
- Close to Kelly geographically
- Strong in translation research

### Regional Cancer Centers
- **UC Davis Comprehensive Cancer Center** — Northern CA
- **UCLA Jonsson Cancer Center** — Los Angeles
- **Cedars-Sinai** — Los Angeles

---

## MEDICAL DEVICE COMPANIES

### Potential Acquirers/Partners

**1. Hamamatsu Photonics** ⭐ EXISTING RELATIONSHIP
- **Status:** Already in conversation
- **Meeting:** Feb 6, 2026 (completed)
- **Interest:** Sensor technology, potential co-development
- **Note:** Do NOT send emails without Kelly's approval

**2. Danaher Corporation**
- **Relevant divisions:** Diagnostics, life sciences
- **Recent:** Acquired multiple diagnostic companies
- **Why target:** Strategic acquirer in diagnostics

**3. Thermo Fisher Scientific**
- **Focus:** Lab equipment, diagnostics
- **Why target:** Could provide manufacturing/distribution

**4. Abbott Laboratories**
- **Relevant:** Point-of-care diagnostics
- **Products:** Various rapid diagnostic tests
- **Why target:** Consumer-facing device experience

**5. Stryker**
- **Note:** Owns MelaFind (competitor)
- **Could be:** Acquirer or competitive threat

### Emerging Medtech
- **DermaSensor** — Competitor, not partner
- **Scibase (Nevisense)** — Competitor

---

## CLINICAL RESEARCH ORGANIZATIONS (CROs)

For clinical trial support:

**1. IQVIA**
- Largest CRO globally
- Full-service trials

**2. Medpace**
- Mid-size, good for diagnostics
- Biotech-focused

**3. Icon**
- Global presence
- Oncology expertise

---

## PARTNERSHIP STRUCTURE OPTIONS

### 1. Clinical Validation Partnership
- Cancer center provides patients/oversight
- HelioFlux provides technology
- Shared publication rights
- **Cost:** Usually $0 (mutual benefit)

### 2. Distribution Partnership
- Dermatology chain gets exclusive/early access
- HelioFlux gets real-world validation
- Revenue share model
- **Value:** Market access + revenue

### 3. Co-Development Partnership
- Device company provides manufacturing expertise
- HelioFlux provides technology/IP
- Joint ownership of resulting product
- **Value:** Speed to market, reduced CapEx

### 4. Strategic Investment
- Partner invests in HelioFlux
- May include partnership terms
- Alignment of interests
- **Value:** Non-dilutive-ish funding + partnership

---

## PRIORITY TARGETS

### Tier 1 (Pursue Now)
1. **Forefront Dermatology** — Largest, best resourced
2. **Moffitt Cancer Center** — Business of Biotech connection
3. **Hamamatsu** — Existing relationship

### Tier 2 (After Validation)
4. **Schweiger Dermatology** — Regional leader
5. **MD Anderson** — Research credibility
6. **Danaher** — Strategic acquirer

### Tier 3 (Long-term)
7. **Abbott** — Consumer device scale
8. **Mayo Clinic** — Top-tier validation
9. **MSK** — NYC presence

---

## ACTION ITEMS

- [ ] Research Forefront Dermatology leadership contacts
- [ ] Follow up on Hamamatsu meeting outcomes
- [ ] Check Moffitt Business of Biotech 2026 dates
- [ ] Draft partnership pitch deck
- [ ] Identify warm intros to dermatology chain executives

---

*Sources: PMC, Axios, Healio, Physician Growth Partners, company websites*
